Author:
Öz Erdoğan,Parlak Mehmet Emin,Kapıcı Yaşar,Balatacı Umut,Küçükkelepçe Osman,Kurt Fatma
Abstract
AbstractThis study aimed to examine potential disparities in hematologic inflammation parameters between children diagnosed with attention deficit hyperactivity disorder (ADHD) and their healthy counterparts and to determine whether atomoxetine treatment induced any alterations in inflammation indicators. This case–control study involved 43 children aged 6–13 years, 22 diagnosed with ADHD for the first time, and 21 healthy children. In all children, complete blood count and albumin, C-reactive protein (CRP), thyroid stimulating hormone (TSH), free thyroxine (free T4), folate, vitamin B12, aspartate aminotransferase (AST), alanine transaminase (ALT), creatinine and urea values were performed. Children with ADHD were started on atomoxetine treatment, and one month later, the blood test was repeated for those who commenced treatment. Neutrophil (p = 0.005), platelet (PLT) (p = 0.002), neutrophil/lymphocyte ratio (NLR) (p = 0.001), platelet/lymphocyte ratio (PLR) (p < 0.001), systemic immune /inflammation index (SII) (p < 0.001) and pan-immune-inflammation value (PIV) (p = 0.025) parameters were found to be significantly higher than the control group, while the lymphocyte value (p = 0.001) was found to be significantly lower. In those in the ADHD group, lymphocyte (p = 0.041) and albumin (p = 0.027) values increased significantly after treatment. The results of this study show the increase in inflammation in drug-naive ADHD patients and the partial improvement after treatment. However, there is a need to evaluate inflammation in larger samples after longer-term treatments and follow-ups.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Akinci, M. A. & Uzun, N. Evaluation of hematological inflammatory markers in children and adolescents with attention deficit/hyperactivity disorder. Bratisl. Lek. Listy 122(4), 256–262 (2021).
2. Sharp, S. I., McQuillin, A. & Gurling, H. M. Genetics of attention-deficit hyperactivity disorder (ADHD). Neuropharmacology 57(7–8), 590–600 (2009).
3. Saccaro, L. F., Schilliger, Z., Perroud, N. & Piguet, C. Inflammation, anxiety, and stress in attention-deficit/hyperactivity disorder. Biomedicines 9(10), 1313 (2021).
4. Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J. & Rohde, L. A. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am. J. Psychiatry 164(6), 942–948 (2007).
5. Mitchell, R. H. & Goldstein, B. I. Inflammation in children and adolescents with neuropsychiatric disorders: A systematic review. J. Am. Acad. Child Adolesc. Psychiatry 53(3), 274–296 (2014).